Welcome to The Biotech Startups Podcast by Excedr. Join us as we speak with first-time founders, experienced scientists, long-time company operators, serial entrepreneurs, and biotech investors about the challenges and triumphs of running a biotech startup. Gain actionable insight into navigating the ever-changing life sciences industry in each episode as we explore the business of science, from pre-seed to IPO. With your host, Jon Chee.
Site
RSS
Apple
Recent rankings
Latest chart positions across Apple Podcasts and Spotify rankings.
Shared links between episodes and podcasts
Links found in episode descriptions and other podcasts that share them.
Discover shows related to The Biotech Startups Podcast, based on actual content similarities. Explore podcasts with similar topics, themes, and formats, backed by real data.
There is no related content for this show.
No links shared by this podcast
RSS feed quality
To improve
Score global : 42%
🧬 Doug Drysdale - Cybin - Part 3 | Jumping from BD to M&A | Leveraging Debt for Strategic Acquisitions | The Importance of Cultural Fit in Successful Deals | Making an Impact at Norwich, Alvogen, & Pernix Therapeutics
Episode 74
Monday, September 2, 2024 • Duration 27:57
Part 3 of 4.
My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics.
Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.
🧬 Doug Drysdale - Cybin - Part 2 | Deals Only Get Done in Person | Learning Financing Through a Company’s Hardship | Bureaucracy in the Workplace | How to Educate Yourself to Determine Good Licensing Deals
Episode 73
Thursday, August 29, 2024 • Duration 31:29
Part 2 of 4.
My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Their goal is to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Doug is an experienced investor, Corporate Director, and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During Doug’s 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents, and raised and invested around $4 billion of public and private capital.
🧬 Shekhar Mitra - InnoPreneur & P&G - Part 1 | Growing Up in a Multigenerational Household | Undergraduate Experience at IIT | Groundbreaking Lab Research at Columbia | Diverse Experiences in New York City
Episode 64
Monday, July 29, 2024 • Duration 44:07
Part 1 of 4.
My guest for this week’s episode is Shekhar Mitra, former Senior Vice President of Global Innovation and Chief of Innovation at Procter & Gamble and current President and Founder of InnoPreneur, a strategic advisory firm that enables development of innovation capabilities, ideation, and organizational development for Fortune 500 corporations and new ventures.
🧬 Nathan Clark - Ganymede - Part 4 | Data Integration & Automation in the Life Sciences | Building a Technical Team & Go-To-Market Motion | Creating Efficient Data Infrastructures | Automating Complex Workflows
Episode 63
Thursday, July 25, 2024 • Duration 35:47
Part 4 of 4.
My guest for this week’s episode is Nathan Clark, Founder and CEO of Ganymede. Ganymede is the modern cloud data platform for the life sciences and manufacturing. Their Lab-as-Code technology allows you to quickly integrate and harmonize lab instruments and app data, automate analysis, visualize all your data in dashboards built over a powerful data lake, and ultimately speed up your operations to accelerate science or production.
🧬 Nathan Clark - Ganymede - Part 3 | Parallels Between Benchling & Salesforce | Getting Customers to Fully Buy-In | Managing the “Writhing Snake of Data” | Ganymede Achieves Escape Velocity Growth
Episode 62
Monday, July 22, 2024 • Duration 29:31
Part 3 of 4.
My guest for this week’s episode is Nathan Clark, Founder and CEO of Ganymede. Ganymede is the modern cloud data platform for the life sciences and manufacturing. Their Lab-as-Code technology allows you to quickly integrate and harmonize lab instruments and app data, automate analysis, visualize all your data in dashboards built over a powerful data lake, and ultimately speed up your operations to accelerate science or production.
🧬 Nathan Clark - Ganymede - Part 2 | Moving from Goldman Sachs to Fintech | Exploring Product Management at Affirm | Leveraging Data & Building Tech Solutions| Impacting Scientific Progress at Benchling
Episode 61
Thursday, July 18, 2024 • Duration 27:39
Part 2 of 4.
My guest for this week’s episode is Nathan Clark, Founder and CEO of Ganymede. Ganymede is the modern cloud data platform for the life sciences and manufacturing. Their Lab-as-Code technology allows you to quickly integrate and harmonize lab instruments and app data, automate analysis, visualize all your data in dashboards built over a powerful data lake, and ultimately speed up your operations to accelerate science or production.
🧬 Nathan Clark - Ganymede - Part 1 | Early Influence of Entrepreneurs | Developing Passions for Both Finance & Life Sciences | Fundamentals of Trading & Finances | Experiences & Opportunities at Goldman Sachs
Episode 60
Monday, July 15, 2024 • Duration 36:43
Part 1 of 4.
My guest for this week’s episode is Nathan Clark, Founder and CEO of Ganymede. Ganymede is the modern cloud data platform for the life sciences and manufacturing. Their Lab-as-Code technology allows you to quickly integrate and harmonize lab instruments and app data, automate analysis, visualize all your data in dashboards built over a powerful data lake, and ultimately speed up your operations to accelerate science or production.
🧬 David Li - Meliora Therapeutics - Part 4 | Mechanism Identification in Biotech | AI & ML in Drug Development | Creating a New Method for Drug Discovery | Fundraising for Meliora | Building a Foundational Startup Team
Episode 59
Thursday, July 11, 2024 • Duration 28:15
Part 4 of 4.
My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.
🧬 David Li - Meliora Therapeutics - Part 3 | Developing a Blood-Based Lung Cancer Test | The Rifle-Shot Nature of Biotech | Software Vs. Biotech Product Market Fit | The Super Power all Startups Need
Episode 58
Monday, July 8, 2024 • Duration 20:14
Part 3 of 4.
My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.
🧬 David Li - Meliora Therapeutics - Part 2 | From Finance to Biotech Entrepreneurship | Building Solid Teams & Navigating Market Dynamics | Lessons in Early-Stage Startups
Episode 57
Wednesday, July 3, 2024 • Duration 25:01
Part 2 of 4.
My guest for this week’s episode is David Li, CEO and co-founder of Meliora Therapeutics. Meliora's goal is to develop life-saving cancer therapies using cutting-edge science and machine learning. The company derives a comprehensive picture of how drugs interact with cancer biology by combining biofunctional readouts from numerous modalities using advanced machine learning and other computational techniques.